Websites linking to gene.com

Breakthrough science. One moment, one day, one person at a time.

Breakthrough science. One moment, one day, one person at a time.

東レが開発した高感度DNAチップ 3D-Gene®。製品・サービスや、3D-Gene®の技術・使用例、DNAチップとは、などをご紹介。

Learn about CIU (chronic idiopathic urticaria). Get info on about recognizing, managing and living with this form of chronic hives.

The XOLAIR Co-pay Card Program can help you with your co-pay for XOLAIR, a treatment for appropriate moderate to severe persistent allergic asthma patients.

Learn about HEMLIBRA® (emicizumab-kxwh), a hemophilia A treatment now approved for people with hemophilia A with factor VIII inhibitors. See BOXED WARNING. What is HEMLIBRA? HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A with factor VIII inhibitors. What is the most important information I should know about HEMLIBRA? HEMLIBRA increases the potential for your blood to clot. Discontinue prophylactic use of bypassing agents the day before starting HEMLIBRA prophylaxis. Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent, and the dose and schedule you should use. HEMLIBRA may cause the following serious side effects when used with aPCC (FEIBA®), including: Thrombotic microangiopathy (TMA). This is a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs. Get medical help right away if you have any of the signs and symptoms of TMA during or after treatment with HEMLIBRA. Blood clots (thrombotic events). Blood clots may form in blood vessels in your arm, leg, lung or head. Get medical help right away if you have any of the signs or symptoms of blood clots during or after treatment with HEMLIBRA. If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total. How should I use Hemlibra? See the detailed “Instructions for Use” that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes. HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and may cause a false reading. Talk to your healthcare provider about how this may affect your care. What are the other possible side effects of HEMLIBRA? The most common side effects of HEMLIBRA include: redness, tenderness, warmth, or itching at the site of injection; headache; and joint pain. These are not all of the possible side effects of HEMLIBRA. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. Please see the HEMLIBRA full Prescribing Information and Medication Guide for more important safety information including Serious Side Effects.

愛知県半田市のヨガスタジオ「スタジオティティー」はだれもがそれぞれ楽しめるスタジオです。ヨガ・ホットヨガ以外にもバレエ・カポエイラ・ダンス・ピラティスなどいろいろなクラスを楽しんで頂けます。 全米ヨガアライアンス認定校（RYS）です。

FAIS（フェイス）は産・官・学の連携・共同研究の促進、国際間の知的交流の推進を目的に1977年9月、経済団体連合会（経団連）が筑波研究学園都市に設立した文部省（現文部科学省）認可の公益法人です。

Explore new research in cancer and learn how Genentech is dedicated to investigating diverse biological pathways and disease targets.

Allergic asthma can turn things like dust and pet dander into real threats. If you avoid these asthma triggers, you may have allergic asthma. Learn more!

株式会社サードジーン[3rdgene Inc.]は3世代先を見据え成長し続ける会社です。キュレーションメディア・ポータルサイト事業、スマートフォンサイト・アプリのプロモーション・コンサルティング事業、サイト制作・アプリ開発等のソリューション事業を行っております。

AIR-GENE是擁有500坪的室內育樂中心，主題區域分為兒童遊憩區／一般彈跳區／專業彈跳區／籃球彈跳區／躲避球彈跳區／極限跑酷區／攀岩區等場地，彈跳器材裝備皆符合國際ASTM規格認證，致力打造全台最高規格、最安全的彈跳床運動場館，場內設施規畫皆通過定期消防逃生安檢項目，所有設施器材皆有定期消毒清潔與更新維護，每位專業

ヴィジーン・トレーディングはエステティックサロンの出店から月々の仕入まで、「成功する」業務用化粧品・店販商品・エステ用品・消耗品・美容エステ機器・ベッドの仕入まで、プロのエステティシャンをサポートします。

Just what exactly does a rheumatologist treat?

Raise awareness of stroke signs and symptoms with educational resources and helpful tools available for order or download on StrokeAwareness.com.

The Lung Cancer Project aims to remove the stigma and barriers faced by people with lung cancer through awareness - so everyone receives the care they deserve.

Patient engagement Software experts help you make mobile applications that delight & empower

شرکت ویراژن آکام وارد کننده تجهیزات و مواد آزمایشگاهی و ژنتیک

Sign up for information and resources for people with Hemophilia A, and for updates on Genentech's research in Hemophilia A.

XOLAIR® (omalizumab) is a treatment for moderate to severe persistent allergic asthma and Chronic Idiopathic Urticaria (CIU) in appropriate patients.

Learn more about Activase® (Alteplase) for Acute Ischemic Stroke Treatment. Indications Activase (alteplase) is indicated for the treatment of acute ischemic stroke. Exclude intracranial hemorrhage as the primary cause of stroke signs and symptoms prior to initiation of treatment. Initiate treatment as soon as possible but within 3 hours after symptom onset. Activase is indicated for use in acute myocardial infarction (AMI) for the reduction of mortality and reduction of the incidence of heart failure. Limitation of Use: The risk of stroke may outweigh the benefit produced by thrombolytic therapy in patients whose AMI puts them at low risk for death or heart failure. Activase is indicated for the lysis of acute massive pulmonary embolism (PE), defined as: • Acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segments. • Acute pulmonary emboli accompanied by unstable hemodynamics, e.g.,failure to maintain blood pressure without supportive measures. Important Safety Information Contraindications Do not administer Activase to treat acute ischemic stroke in the following situations in which the risk of bleeding is greater than the potential benefit: current intracranial hemorrhage (ICH); subarachnoid hemorrhage; active internal bleeding; recent (within 3months) intracranial or intraspinal surgery or serious head trauma; presence of intracranial conditions that may increase the risk of bleeding; bleeding diathesis; and current severe uncontrolled hypertension. Do not administer Activase to treat acute myocardial infarction or pulmonary embolism in the following situations in which the risk of bleeding is greater than the potential benefit: active internal bleeding; history of recent stroke; recent (within 3months) intracranial or intraspinal surgery or serious head trauma; presence of intracranial conditions that may increase the risk of bleeding; bleeding diathesis; and current severe uncontrolled hypertension. Warnings and Precautions Bleeding Activase can cause significant, sometimes fatal, internal or external bleeding, especially at arterial and venous puncture sites.Avoid intramuscular injections and trauma to the patient. Fatal cases of hemorrhage associated with traumatic intubation in patients administered Activase have been reported. Heparin, aspirin, or Activase may cause bleeding complications; therefore carefully monitor for bleeding. If serious bleeding occurs, terminate the Activase infusion. Orolingual Angioedema Monitor patients during and for several hours after infusion for orolingual angioedema. If angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy. Cholesterol Embolization Cholesterol embolism, sometimes fatal, has been reported rarely in patients treated with thrombolytic agents. Reembolization of Deep Venous Thrombi during Treatment for Acute Massive Pulmonary Embolism Consider the possible risk of reembolization due to the lysis of underlying deep venous thrombi patients with acute massive PE Coagulation Tests May be Unreliable during Activase Therapy Coagulation tests and/or measures of fibrinolytic activity may be unreliable during Activase therapy. Adverse Reactions The most frequent adverse reaction associated with Activase therapy is bleeding. Allergic‑type reactions, e.g.,anaphylactoid reaction, laryngeal edema, orolingual angioedema, rash, and urticaria have been reported.

Find helpful resources for managed care and health system decision makers from Genentech, including oncology cost containment trends and care management workshops.

Learn more about single-bolus TNKase® (tenecteplase) acute myocardial infarction treatment and the 5-second TNKase® dosing and administration. Indication For use in mortality reduction associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms. Important Safety Information TNKase therapy in patients with acute myocardial infarction is contraindicated in the following certain situations (eg, active internal bleeding, history of cerebrovascular accident, known bleeding diathesis, severe uncontrolled hypertension) because of an increased risk of bleeding [See CONTRAINDICATIONS in full prescribing information]. The most common complication encountered during TNKase therapy is bleeding. Should serious bleeding (not controlled by local pressure) occur, any concomitant heparin or antiplatelet agents should be discontinued immediately. In certain conditions (eg, recent major surgery, cerebrovascular disease, hypertension) the risk of TNKase therapy may be increased and should be weighed against the anticipated benefits. [See WARNINGS in full prescribing information]. Cholesterol embolism has been reported rarely in patients treated with all types of thrombolytic agents; the true incidence is unknown. Coronary thrombolysis may result in arrhythmias associated with reperfusion. It is recommended that anti-arrhythmic therapy for bradycardia and/or ventricular irritability be available when TNKase is administered. Please see full Prescribing Information for additional important safety information.

Find information for healthcare professionals about Rituxan® (rituximab), the only FDA-approved treatment proven to induce remission in patients with GPA and MPA. INDICATION STATEMENT - Rituxan® (rituximab), in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) - Limitations of Use: Rituxan is not recommended for use in patients with severe, active infections BOXED WARNINGS and Additional Important Safety Information BOXED WARNINGS Infusion Reactions: Rituxan administration can result in serious, including fatal, infusion reactions. Deaths within 24 hours of Rituxan infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Monitor patients closely. Discontinue Rituxan infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion reactions. Severe Mucocutaneous Reactions: Severe, including fatal, mucocutaneous reactions can occur in patients receiving Rituxan. Hepatitis B Virus (HBV) Reactivation: HBV reactivation can occur in patients treated with Rituxan, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with Rituxan. Discontinue Rituxan and concomitant medications in the event of HBV reactivation. Progressive Multifocal Leukoencephalopathy (PML): PML, including fatal PML, can occur in patients receiving Rituxan. Warnings and Precautions Rituxan administration can also result in additional serious, including fatal, adverse reactions including: - Tumor lysis syndrome (TLS): Administer aggressive intravenous hydration, anti‑hyperuricemic agents, monitor renal function - Infections: Withhold Rituxan and institute appropriate anti-infective therapy - Cardiac arrhythmias and angina: Discontinue infusions in case of serious or life-threatening events - Bowel obstruction and perforation: Consider and evaluate for abdominal pain, vomiting, or related symptoms - Live virus vaccines: Do not administer live virus vaccines prior to or during Rituxan - Cytopenias: Monitor blood counts at regular intervals Granulomatosis With Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) - Use of concomitant immunosuppressants other than corticosteroids has not been studied in GPA or MPA patients exhibiting peripheral B-cell depletion following treatment with Rituxan. Observe patients with GPA and MPA closely for signs of infection if immunosuppressants other than corticosteroids are used concomitantly - The safety and efficacy of retreatment with Rituxan have not been established in patients with GPA and MPA - Common adverse reactions (≥15%) in the clinical study were infections, nausea, diarrhea, headache, muscle spasms, anemia, and peripheral edema. Other important adverse reactions include infusion reactions You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. For additional safety information, please see the Rituxan full prescribing information, including BOXED WARNINGS.

JINGU STADIUM NIGHT YOGAの開催情報をお伝えするサイトのトップページ

The B+ Foundation is about kids helping kids fight cancer through family assistance, research and advocacy. Learn more on our homepage.

弘前初のヨガ専門スタジオがヒロロ2階に2016年4月27日にオープン。多彩なヨガプログラムに青森初のヨガ用品ブランドによるウェア、プロップスを販売しております。シニア、初心者が参加しやすいヨガレッスンが多数ご用意しております。

Chinese American Chromatography Association

沖縄県那覇市西町にある、ヨガスタジオ、ヨーガ・シャンティ。瞑想や呼吸法を用いたレッスンで、あなたに自分と向き合う感覚をもたらします。瀬長島温泉ホテルや東浜カルチャーセンターでもレッスン中！

RISHIKESH YOGASHALA（リシケシ・ヨガシャラ）は、真理＆ニシュー・プラサードが主宰するインド伝統式ヨガスクールです。ヨガの奥なる聖地、ヒマラヤ伝承の真正なヨガの教えをベースにした多彩なプログラムを展開しています。初心者・男性・中高年歓迎！ヨガ指導者を目指したい方やもっと深くヨガの学びを深めたい方には、インド中央政府公認＆全米ヨガアライアンス認定ヨガ指導者養成コースもあり。JR町田駅ターミナル口徒歩5分。小田急線町田駅徒歩8分。町田駅前通り、ライオンズルーセント町田正面玄関前。月四回コース：4000円/一ヶ月通い放題5980円/シニアパス一ヶ月4500円（全税込）

Just another WordPress site

Support for people with cancer who are trying to manage their cancer and their career. Answers and advice for working through treatment, FMLA, and managing insurance and cancer.

Six games, countless ways to fight cancer! Play online now for free. Based on scientific research, Re-Mission 2 games provide cancer support for kids and young adults facing the fight of their lives. Play, fight, WIN!

暗号通貨・仮想通貨(ビットコイン、イーサムリアなど)関連の最新ニュース、新規ICOの銘柄特徴やトークンセール情報・ICOスケジュール、仮想通貨取引所の情報などの情報を掲載中！仮想通貨の始め方がわからない初心者〜ICO銘柄情報を集めている上級者まで、仮想通貨情報はCOINews！

自分らしいヨガウェアを提案する通販サイト。オシャレなヨガウェアやグッズに特化したオンラインショップです。国内外からのセレクトであなたの探していたアイテムもきっと見つかるはず！初心者から上級者、ホットヨガから常温ヨガを実践している多くの方々にご利用いただいています。

Spring Bioscience provides targeted high-value product portfolio for cancer researchers, including our line of SP Clone Rabbit Monoclonal antibodies.

世田谷でヨガをはじめるなら岩盤ホットヨガで気持ちよく汗をかく!京王線・世田谷線「下高井戸駅」からほど近いダイエット・岩盤ヨガスタジオ「Ruby Hot Yoga & Relaxation（ルビーホットヨガ&リラクゼーション）」にお任せ下さい。リフレクソロジー、ボディトリートメントメニューもございます!

『YOGAsmile2015春、テーマは”芯”』 真実を学び、内側の「芯」を意識し、 バランスを保つ。 豊かな心を育むために。 新緑の美しい季節、、 芯を感じ、広がり伸び行く 心と身体を感じましょう。

Rheumatology Nurses Society (RNS) is a professional organization committed to the development and education of nurses to benefit its members, patients, family and community.

SGO Society of Gynecologic Oncology

We are a fun group of FileMaker fanatics who enjoy flexing our FileMaker consulting, developing and training skills to help our clients. Let us help you

Lean Construction Institute (LCI) is a non-profit organization that operates as a catalyst to transform the industry through Lean project delivery.

ベータヨガトレーニングは男性だけが参加できるメンズヨガイベント。経営者やエグゼクティブ、トップアスリートが身体と精神面に効果を感じるヨガを東京・大阪にて定期開催中！1クラス2500円のお手頃価格でヨガ初心者でも安心して参加可能！

SNO - Society for Neuro-Oncology